Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study
- PMID: 38758370
- PMCID: PMC11369007
- DOI: 10.1007/s00259-024-06759-x
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study
Abstract
Purpose: Here, we evaluate a PET displacement model with a Single-step and Numerical solution in healthy individuals using the synaptic vesicle glycoprotein (SV2A) PET-tracer [11C]UCB-J and the anti-seizure medication levetiracetam (LEV). We aimed to (1) validate the displacement model by comparing the brain LEV-SV2A occupancy from a single PET scan with the occupancy derived from two PET scans and the Lassen plot and (2) determine the plasma LEV concentration-SV2A occupancy curve in healthy individuals.
Methods: Eleven healthy individuals (five females, mean age 35.5 [range: 25-47] years) underwent two 120-min [11C]UCB-J PET scans where an LEV dose (5-30 mg/kg) was administered intravenously halfway through the first PET scan to partially displace radioligand binding to SV2A. Five individuals were scanned twice on the same day; the remaining six were scanned once on two separate days, receiving two identical LEV doses. Arterial blood samples were acquired to determine the arterial input function and plasma LEV concentrations. Using the displacement model, the SV2A-LEV target engagement was calculated and compared with the Lassen plot method. The resulting data were fitted with a single-site binding model.
Results: SV2A occupancies and VND estimates derived from the displacement model were not significantly different from the Lassen plot (p = 0.55 and 0.13, respectively). The coefficient of variation was 14.6% vs. 17.3% for the Numerical and the Single-step solution in Bland-Altman comparisons with the Lassen plot. The average half maximal inhibitory concentration (IC50), as estimated from the area under the curve of the plasma LEV concentration, was 12.5 µg/mL (95% CI: 5-25) for the Single-Step solution, 11.8 µg/mL (95% CI: 4-25) for the Numerical solution, and 6.3 µg/mL (95% CI: 0.08-21) for the Lassen plot. Constraining Emax to 100% did not significantly improve model fits.
Conclusion: Plasma LEV concentration vs. SV2A occupancy can be determined in humans using a single PET scan displacement model. The average concentration of the three computed IC50 values ranges between 6.3 and 12.5 µg/mL. The next step is to use the displacement model to evaluate LEV occupancy and corresponding plasma concentrations in relation to treatment efficacy.
Clinical trial registration: NCT05450822. Retrospectively registered 5 July 2022 https://clinicaltrials.gov/ct2/results? term=NCT05450822&Search=Search.
Keywords: Displacement; Half maximal inhibitory concentration; Healthy volunteers; Levetiracetam; Occupancy; PET kinetic modeling.
© 2024. The Author(s).
Conflict of interest statement
GMK: Has, within the last 3 years, served as a speaker for Angelini, Abbvie, Compass, and H. Lundbeck and as a consultant for Sanos, Gilgamesh, Pure Technologies, Onsero, and Pangea Botanica. LHP: Has received honoraria as a speaker for Eisai and UCB. MRMJ: Received sponsorship from Jazz Pharmaceuticals for attendance at the 14th European Epilepsy Congress. All other authors declare no conflict of interest.
Figures




Similar articles
-
A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.Epilepsia. 2019 May;60(5):958-967. doi: 10.1111/epi.14701. Epub 2019 Mar 29. Epilepsia. 2019. PMID: 30924924 Free PMC article. Clinical Trial.
-
Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.J Nucl Med. 2016 May;57(5):777-84. doi: 10.2967/jnumed.115.168179. Epub 2016 Feb 4. J Nucl Med. 2016. PMID: 26848175
-
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A.EJNMMI Res. 2022 Nov 8;12(1):71. doi: 10.1186/s13550-022-00944-5. EJNMMI Res. 2022. PMID: 36346513 Free PMC article.
-
Imaging of Synaptic Density in Neurodegenerative Disorders.J Nucl Med. 2022 Jun;63(Suppl 1):60S-67S. doi: 10.2967/jnumed.121.263201. J Nucl Med. 2022. PMID: 35649655 Review.
-
Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications.Drug Discov Today Technol. 2017 Nov;25:45-52. doi: 10.1016/j.ddtec.2017.11.003. Epub 2017 Dec 1. Drug Discov Today Technol. 2017. PMID: 29233267 Review.
References
-
- World Health Organization. Epilepsy: a public health imperative., 2019.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical